Comprehensive compilation of peer-reviewed research on addiction neuroscience, evidence-based treatments, harm reduction strategies, and recovery science. Empowering communities through knowledge.
Increased incentive salience, basal ganglia circuits, dopamine-driven reward activation
Decreased brain reward, increased stress, extended amygdala involvement, negative reinforcement
Compromised executive function, prefrontal cortex impairment, memory systems engaged
Reward processing, habit formation, incentive salience mechanisms
Stress response, negative emotional states, withdrawal symptoms
Executive function, decision-making, risk assessment, impulse control
Key Insight: Addiction involves "usurpation of motivation" - powerfully reinforcing effects that drive compulsive use despite consequences.
Brain areas responsible for evaluating risk and making decisions are not fully developed until mid-20s. Individuals who begin using substances earlier in life consume more frequently and have higher rates of substance use disorders. This critical developmental period requires targeted prevention efforts.
Targets thoughts, behaviors, and coping skills. Includes motivational interviewing, contingency management, and relapse prevention strategies.
Medications alongside behavioral therapies to treat opioid use disorders. Reduces cravings, prevents withdrawal, and blocks euphoric effects.
Supervised injection sites, naloxone distribution, needle exchange. Meets people where they are, reduces negative consequences without requiring abstinence.
Deaths decreased from 253 to 165 per 100K PYs among residents within 500m of facility
Monthly calls decreased from 27 to 9 near facility
Before SIS: 35% of IV drug users admitted over 3 years, 15% for skin infections
After SIS: 9% admitted with injection-related infections
8-day reduction in average hospital stay
Mathematical modeling: 6-57 HIV infections prevented per year per facility
Harm reduction is a public health approach that meets people where they are, reducing negative consequences of substance use without requiring abstinence. Evidence demonstrates that these strategies save lives, reduce disease transmission, decrease emergency service burden, and provide pathways to treatment—all while respecting individual autonomy and dignity.
Research shows that longer treatment duration is associated with significantly higher rates of sustained recovery. Programs of 90 days or longer demonstrate the most dramatic improvements in brain function and behavioral outcomes.
Brain Recovery During Abstinence
The brain demonstrates remarkable neuroplasticity during sustained abstinence. While the full extent of recovery capacity is still being studied, evidence shows measurable improvements in executive function, decision-making, and emotional regulation over time.
Social Support Networks
Peer support, family involvement, community connections
Meaningful Activities
Employment, education, hobbies, purpose-driven work
Continued Care
Ongoing therapy, support groups, medication management
Stable Housing & Income
Safe environment, financial security, reduced stressors
Trauma-Informed Care
Addressing co-occurring PTSD, integrated treatment approaches
History of trauma and PTSD are highly common among individuals with substance use disorders and are associated with poorer treatment retention and outcomes. Integrated trauma-informed approaches that simultaneously address substance use and trauma symptoms demonstrate improved retention and better long-term recovery outcomes.
Over 70% of individuals entering substance abuse treatment report trauma exposure. PTSD rates are significantly higher in treatment populations than general population.
Integrated trauma-informed care improves treatment retention, reduces PTSD symptoms, and enhances ability to manage substance use in the year following treatment.
Creating physically and emotionally safe environments for healing
Transparent operations and consistent, reliable care delivery
Mutual support and shared experiences in recovery
Shared decision-making and power-sharing in treatment
Building on strengths and fostering self-advocacy
Recognizing diverse backgrounds and lived experiences
Uhl GR, Koob GF, Cable J. Ann N Y Acad Sci. 2019 Jan 15;1451(1):5-28
View on PMC →McHugh RK, Hearon BA, Otto MW. Psychiatr Clin North Am. 2010 Sep;33(3):511–525
View on PMC →Ng J, Sutherland C, Kolber MR. Can Fam Physician. 2017 Nov;63(11):866
View on PMC →Note: This resource compilation is based on peer-reviewed research from the National Institutes of Health (NIH), PubMed Central (PMC), and other reputable scientific sources. All statistics and findings are cited from published studies. For complete references and methodology, please refer to the original research papers linked above.
ADUA Coin funds research, harm reduction programs, and evidence-based treatment initiatives. Join us in transforming addiction care through blockchain innovation and scientific knowledge.